CD8A and neoplasm: Therefore, a consensus Immunoscore has been developed as a standardized, reproducible assay that may accurately predict recurrence risk and overall survival in CRC by primarily quantifying mostly CD3+ and CD8+ T-cell infiltration in the tumor center and invasive margin (20).